<DOC>
	<DOCNO>NCT01622361</DOCNO>
	<brief_summary>The purpose study compare neo-adjuvant therapy cytotoxic chemotherapy versus GnRHa tamoxifen , response rate ( RR ) patient hormone responsive HER2 negative , lymph node positive , primary breast cancer premenopausal woman .</brief_summary>
	<brief_title>Premenopausal Patient With Hormone Responsive , HER2 Negative , Lymph Node Positive Breast Cancer</brief_title>
	<detailed_description>1 . Primary objective : Response Rate-MRI and/or Caliper 2 . Secondary objective - Pathologic complete response - Rate conservation surgery - Ki-67 change relationship treatment response - Length time maximum response within treatment period - Tolerability two treatment - Disease-free survival ( DFS ) - Overall survival</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>1 . Histologically proven primary invasive breast cancer think suitable neoadjuvant treatment 2 . Pathologically proven lymph node positive tumor ( FNAB Core biopsy ) 3 . Tumor must ER positive ( eligible patient include Allred score 5 , Modified Allred 4 ) HER2 negative ( IHC score 01+ ; If IHC score 2+ , result FISH SISH negative ) 4 . Premenopausal woman Premenopausal status define : Last menses within 6 month randomization For patient unilateral oophorectomy , E2 ≥ 20PG/mL FSH &lt; 30mIU/Ml within 4 week randomization 5. 20 year old 6 . Pretreatment haematology biochemistry value within acceptable limit : ANC ≥ 1.5 × 109/l Hb &gt; 9g/dl Platelets ≥ 100 × 109/l AST/ALT ≤ 1.5 × ULN ( Upper Limit Normal ) ALP ≤ 1.5 × ULN Serum bilirubin ≤ 1.5 × ULN Serum creatinine ≤ 1.5 × ULN 7 . ECOG PS 0 1 8 . No concomitant medical , psychiatric geographic problem might prevent completion treatment followup 9 . Before studyspecific procedure , appropriate write informed consent must obtain 1 . Inflammatory breast cancer 2 . Inoperable disease judge unlikely render operable neoadjuvant treatment 3 . Known severe hypersensitivity GnRHa treatment 4 . Bilateral invasive breast cancer 5 . Other serious illness medical condition : congestive heart failure unstable angina pectoris , previous history myocardial infarction within 1 year study entry , uncontrolled hypertension highrisk uncontrolled arrhythmias history significant neurologic psychiatric disorder include psychotic disorder , dementia seizure would prohibit understanding give informed consent active uncontrolled infection 6 . HRT within 4 week start treatment 7 . Definite contraindication use corticosteroid . 8 . Last 10 year history malignant tumor ( except case basal cell carcinoma cervical carcinoma situ , treatment consist solely resection ) 9 . Systemic metastatic ( Tests diagnosis systemic metastatic comply guideline institution ) 10 . Pregnant breastfeed woman 11 . Chronic oral treatment corticosteroid unless initiate &gt; 6 month prior study entry low dose ( ≤ 20 mg methylprednisolone equivalent ) .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Neoadjuvant</keyword>
	<keyword>endocrine therapy</keyword>
	<keyword>premenopausal</keyword>
	<keyword>hormone responsive</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>lymph node positive</keyword>
</DOC>